QURE | Biotech Message Board Posts

Biotech   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27323 of 28402  at  5/16/2019 11:32:54 AM  by



 uniQure jumps after Chardan boosts price target to $175 from $100Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease. The stock in morning trading is up 4.5%, or $2.63, to $61.64. uniQure, a Chardan Top Pick for 2019, could be headed towards a $5B-$10B valuation as support emerges for what could be a "best-in-class, breakthrough" Huntington's disease franchise, Amusa tells investors in a research note. In the second half of 2019, uniQure is expected to make AMT-130 the first one-time gene theraphy to enter the clinic for Huntington's, the analyst adds. Following due diligence, Amusa now expects peak AMT-130 sales of $2.7B, 25% risk-adjusted, in 2026. While the market opportunity for Huntington's is potentially larger than that for Duchenne muscular dystrophy, uniQure does have some analogy to Sarepta Therapeutics (SRPT), which moved up 114% in 2018, Amusa writes. He keeps a Buy rating on uniQure shares.

Read more at:

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 93
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by